Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78


Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.

Pascolutti R, Sun X, Kao J, Maute RL, Ring AM, Bowman GR, Kruse AC.

Structure. 2016 Oct 4;24(10):1719-1728. doi: 10.1016/j.str.2016.06.026. Epub 2016 Sep 8.


Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.

Guzik K, Zak KM, Grudnik P, Magiera K, Musielak B, Törner R, Skalniak L, Dömling A, Dubin G, Holak TA.

J Med Chem. 2017 Jul 13;60(13):5857-5867. doi: 10.1021/acs.jmedchem.7b00293. Epub 2017 Jun 23.


Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.

Liu W, Huang B, Kuang Y, Liu G.

Mol Biosyst. 2017 May 2;13(5):892-900. doi: 10.1039/c7mb00036g.


Human PD-1 binds differently to its human ligands: a comprehensive modeling study.

Viricel C, Ahmed M, Barakat K.

J Mol Graph Model. 2015 Apr;57:131-42. doi: 10.1016/j.jmgm.2015.01.015. Epub 2015 Feb 14.


Regulation of PD-L1: a novel role of pro-survival signalling in cancer.

Chen J, Jiang CC, Jin L, Zhang XD.

Ann Oncol. 2016 Mar;27(3):409-16. doi: 10.1093/annonc/mdv615. Epub 2015 Dec 17. Review.


PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.

Sun X, Yan X, Zhuo W, Gu J, Zuo K, Liu W, Liang L, Gan Y, He G, Wan H, Gou X, Shi H, Hu J.

Int J Mol Sci. 2018 Jul 7;19(7). pii: E1984. doi: 10.3390/ijms19071984.


Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang L.

J Thorac Oncol. 2015 Jun;10(6):910-23. doi: 10.1097/JTO.0000000000000500.


Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).

Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Dömling A, Dubin G, Holak TA.

Oncotarget. 2016 May 24;7(21):30323-35. doi: 10.18632/oncotarget.8730.


Structure and interactions of the human programmed cell death 1 receptor.

Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, Huo J, Yu C, Evans EJ, Leslie AJ, Griffiths M, Stubberfield C, Griffin R, Henry AJ, Jansson A, Ladbury JE, Ikemizu S, Carr MD, Davis SJ.

J Biol Chem. 2013 Apr 26;288(17):11771-85. doi: 10.1074/jbc.M112.448126. Epub 2013 Feb 15.


Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Meng X, Huang Z, Teng F, Xing L, Yu J.

Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10. Review.


Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.

Mitteldorf C, Berisha A, Pfaltz MC, Broekaert SMC, Schön MP, Kerl K, Kempf W.

Am J Surg Pathol. 2017 Jul;41(7):998-1004. doi: 10.1097/PAS.0000000000000851.


Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA.

Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.


Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA.

Structure. 2015 Dec 1;23(12):2341-2348. doi: 10.1016/j.str.2015.09.010. Epub 2015 Oct 22.


Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.

Shi D, Zhou S, Liu X, Zhao C, Liu H, Yao X.

Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):576-588. doi: 10.1016/j.bbagen.2017.11.022. Epub 2017 Dec 2.


Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.

He G, Zhang H, Zhou J, Wang B, Chen Y, Kong Y, Xie X, Wang X, Fei R, Wei L, Chen H, Zeng H.

J Exp Clin Cancer Res. 2015 Nov 18;34:141. doi: 10.1186/s13046-015-0256-0.


The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S.

Haematologica. 2013 Jun;98(6):953-63. doi: 10.3324/haematol.2012.077537. Epub 2013 Jan 8.


Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.

Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS.

PLoS One. 2015 Apr 22;10(4):e0124059. doi: 10.1371/journal.pone.0124059. eCollection 2015.


Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.

Merelli B, Massi D, Cattaneo L, Mandalà M.

Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002. Epub 2013 Aug 28. Review.


A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner.

Schuster C, Brosi H, Stifter K, Boehm BO, Schirmbeck R.

PLoS One. 2013 Aug 19;8(8):e71746. doi: 10.1371/journal.pone.0071746. eCollection 2013.


PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).

Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, Raderer M, Preusser M.

Clin Neuropathol. 2014 Jan-Feb;33(1):42-9.


Supplemental Content

Support Center